StockData

Enanta Pharmaceuticals vs Septerna

ENTA and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTA and SEPN compare

Septerna is the larger company, worth 7.4 times as much as Enanta Pharmaceuticals ($1.9B against $253M).

Septerna grew revenue faster over the last twelve months (337% versus −3.6% for Enanta Pharmaceuticals).

Septerna keeps more of each dollar of sales as profit, with a net margin of −61.3% compared with −108% at Enanta Pharmaceuticals.

Septerna scores higher on the StockData Score (8 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTASEPN
Size and price
Market cap$253M$1.9B
Share price$8.69$40.02
Change, 1 year−27.9%72.0%
Change, 5 years−90.5%–
Beta (5Y)1.730.70
Employees120130
StockData Score
Total score28 (better)
Valuation score00
Growth score01 (better)
Performance score11
Health score16 (better)
Dividend score00
Valuation
P/S4.0× (better)19.4×
P/B3.2× (better)4.4×
FCF yield−16.9%−4.2% (better)
Fair value$8.53$15.08
Margin of safety−1.8% (better)−165%
Growth
Revenue growth (TTM)−3.6%337% (better)
Revenue growth, 5Y average−8.3%–
Profitability
Operating margin−99.0%−76.2% (better)
Net margin−108%−61.3% (better)
FCF margin−67.9% (better)−80.6%
Return on equity−94.2%−14.4% (better)
Financial health
Debt / equity–0.00
Interest coverage−4.4×–
Current ratio3.784.84 (better)
Altman Z-score−1.495.91 (better)
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.6%102%
Held by insiders7.9%27.9%
Insider net buying, 12 months−$183K (better)−$80.9M
Short interest, % of float6.9%10.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.